32 results about "Behavioural disorders" patented technology

The invention belongs to the technical field of traditional Chinese medicine compound preparations, and particularly relates to a qi-regulating, phlegm-reducing and nerve-calming paste, a preparation method thereof and application of the paste in preparation of a medicine for treating Parkinson's disease combined with rapid eye movement sleep behavior disorder. The paste is prepared from the following raw materials in parts by weight: 9-30 parts of semen ziziphi spinosae, 15-30 parts of Chinese yam, 10-15 parts of poria with hostwood, 9-30 parts of semen coicis, 3-10 parts of pericarpium citri reticulatae, 3-10 parts of fingered citron, 10-20 parts of sesame, 10-20 parts of rock candy and 3-5 parts of maltose. By nourishing the heart and strengthening the spleen to consolidate the root, regulating qi and reducing phlegm to relieve stagnation and tranquilizing and sedating the physique to return to the soul, the three methods are combined to achieve the purposes of tonifying without stagnation, eliminating without injury, recovering the heart and the spleen, smoothing phlegm and qi and self-hiding the soul.

The invention provides a vision detection method, device and equipment and a medium. The method comprises the following steps: acquiring a bio-electricity signal set of a detection object; inputting the bio-electricity signal set into a vision detection model to obtain a detection result set corresponding to the bio-electricity signal set; based on each detection result, determining a target vision detection identifier from a vision detection identifier set; and determining the target vision level of the detection object according to the target detection identifier. Vision detection is carried out by collecting the bio-electricity signal set of the detection object, and the behavior of the detection object does not need to be used as feedback of vision detection, so that the vision detection of people with behavior disorder has feasibility. Besides, through the corresponding form of the vision detection identifier set and the bio-electricity signal set, a more comprehensive vision detection result can be obtained, so that the vision detection result of the user is more accurate.

The invention discloses a method for improving autism behaviors through Npas4 expression and overexpression in a cat chat syndrome model, and belongs to the technical field of animal model construction. Selecting SD wild rats and CdCS model rats, and normally feeding and breeding the rats; the method comprises the following steps: measuring the protein concentration by adopting a BCA method, then carrying out Western Blot, then carrying out brain stereotactic injection, and finally carrying out behavioral testing. According to the invention, a CdCS rat model is established by using a CRISPR-Cas9 technology, and the model shows cognitive and social behavior disorders and medial prefrontal cortex (mPFC) neuron dendritic abnormality; in addition, an abnormally expressed gene is found in the model mouse, the research focuses on Npas4, and a new insight is possibly provided for disease treatment.

The present invention relates to a peptide mixture, a method for obtaining a hydrolysate, and the hydrolysate obtained using this method. The invention also relates to the use of the peptide mixture and the hydrolysate as additives in animal feed to improve growth and / or increase physical performance and / or prevent and / or treat stress and / or behavioural disorders.

The invention discloses a method for constructing a social anomaly mouse model, relates to the technical field of animal model construction, and constructs a social anomaly model of a filial generation mouse by performing bisphenol S exposure on a female mouse in a pregnancy and nursing period. According to the mouse model constructed by the invention, in the pregnancy and nursing period, BPS is exposed, and the development of left secondary motor cortex neurons is damaged, so that progeny is induced to have social behavior disorder; the activity of neurons in the left M2 brain region is activated, so that social behavior disorders can be effectively relieved. The invention not only clarifies the neural development mechanism of the environmental endocrine disrupter-induced autism-like social disorder, but also provides a new thought of activating left M2 neurons as a potential intervention means, and can be used for developing drugs for treating the social behavior disorder induced by the environmental endocrine disrupter; the invention provides a new direction for etiological research and treatment strategy exploration of neurodevelopment disorder diseases taking social defects as core symptoms, and is beneficial to promoting deep development of related medical research.

The present technology relates to methods of treating behavioral problems and seizures in a subject having developmental and epileptic encephalopathy (DEE) by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein behavioral problems are treated in the subject.

The invention relates to a pharmaceutical composition for treating diseases induced by sleep deprivation and application of the pharmaceutical composition, and belongs to the technical field of medicines.The pharmaceutical composition is prepared from 5-60 parts of honey-fried licorice roots, 5-35 parts of dried ginger, 5-35 parts of radix paeoniae alba, 5-35 parts of cinnamon, 5-35 parts of panax notoginseng and 2-12 parts of leeches. The pharmaceutical composition disclosed by the invention can be used for effectively treating or improving diseases such as neuroinflammation, cognitive behavior disorder, blood-brain barrier injury, intestinal leakage and the like induced by sleep deprivation, and these effects prove that the pharmaceutical composition disclosed by the invention can be used for effectively treating or relieving related diseases induced by sleep deprivation.

This invention provides a treatment for patients with developmental and epileptic encephalopathy (DEE) that addresses behavioral problems in addition to seizures, without causing undesirable side effects such as somnolence, lethargy, withdrawal, and sedation. [Solution] A method is provided for treating behavioral problems and seizures in a subject having DEE, comprising administering an effective amount of cannabidiol (CBD) transdermally to the subject, wherein the behavioral problems are treated in the subject.

Detection of fast eye movement (REM) sleep and associated abnormalities is important for identifying various nervous system diseases. The present disclosure relates to the detection of time intervals during which a subject is in REM sleep by utilizing electroencephalogram (EEG) data from selective spectral frequencies. The techniques as disclosed herein may use one or more EEG electrodes, and more particularly, single channel EEG signals provide a simple and cost-effective solution. The disclosed techniques may pre-process the EEG data, extract features and / or derived features for one or more time intervals from selective spectral bands (e.g., delta and gamma). These extracted features may be normalized and clustered to further determine REM, non-REM, and waking time intervals. By using one or more non-EEG sensors to detect the presence of muscular tension of the identified REM sleep intervals, and by performing sleep pattern analysis, potential REM intervals can be verified to detect REM behavioral disorders.

This invention discloses the application of bimatoprost in the preparation of drugs for the prevention and / or treatment of Parkinson's disease, within the field of drug reuse. Bimatoprost is a prostaglandin F2α analog, currently mainly used for glaucoma and eyelash growth. This invention has found that bimatoprost can improve Parkinson's disease-related behavioral disorders, increase the expression of tyrosine hydroxylase, a protein associated with dopaminergic neurons in the substantia nigra, and reduce the abnormal accumulation of α-synuclein, thus exhibiting good ameliorative and protective effects against Parkinson's disease. This invention provides a new drug option for the treatment of Parkinson's disease.

To provide methods for diagnosing and treating conduct disorder.SOLUTION: Diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes, and the treatment is performed with nonselective activators of mGluRs such as fasoracetam.SELECTED DRAWING: None

The present invention provides pharmaceutical composition for the treatment of tauopathy-related diseases that can significantly improve cognitive and behavioral impairments by reducing neuronal uptake and propagation of disease-associated tau.

The invention discloses a mild behavioral disorder cognitive decline prediction method based on multi-modal image fusion, and relates to the technical field of mild cognitive impairment prediction. According to the method, feature vectors of different modes are spliced to form a joint feature matrix, redundant information is eliminated through principal component analysis, and main variation components are reserved; inputting the feature set after dimension reduction into a prediction model based on machine learning, optimizing hyper-parameters through cross validation, and training a classifier so as to identify a cognitive decline risk mode of the patient with the mild behavioral disorder; multi-modal image data are received in real time through a standardized API interface, a prediction algorithm is automatically executed, and a report including individualized risk scores, confidence intervals, risk level classification and interpretability analysis is generated; the report is output in a structured format, so that a clinician can quickly refer to the report in the diagnosis process, meanwhile, the report is supported to be exported in a PDF or electronic health record format, and seamless integration with an existing medical information system is ensured.

Pyridazine based compounds and pharmaceutical compositions that may be used for treating synaptic and behavioral dysfunction such as that associated with Alzheimer's Disease, tauopathies, Alzheimer's Disease related dementia, and other dementia. Compounds disclosed herein can be used for treatment of neuropsychiatric, cognitive or behavioral disorders, especially those associated with neurodegenerative disorders. Also disclosed is a method for treating neuropsychiatric, cognitive or behavioral disorders in a subject suffering from a neurodegenerative disease by administering these compounds and pharmaceutical compositions to a subject in need thereof.

The invention relates to the field of animal models, in particular to a preparation method of a fast eye movement sleep behavior disorder animal model with cytopathology specificity, which comprises the following steps: injecting adeno-associated virus for inducing neuronal overexpression alpha-synuclein into a capped karyobrain area on the back and the outer side of a non-human tested animal, and injecting the neuron-derived extracellular vesicles or the oligodendroglia-derived extracellular vesicles into the capped karyocerebral region on the back outer side of the non-human tested animal again. The model prepared by the method disclosed by the invention has the disease characteristics of fast eye movement sleep and has the characteristic that Parkinson-like phenotype is transformed. The model disclosed by the invention can be used for researching the etiology and pathological mechanism of transformation of rapid eye movement sleep behavior disorder to Parkinson's disease or multi-system atrophy and screening prevention and treatment drugs, and has remarkable significance for clinically providing effective drug treatment targets and prevention and treatment means.

Detecting rapid eye movement (REM) sleep and associated abnormalities can be significant for identifying various neurological disorders. The present disclosure relates to detection of time intervals during which a subject is in REM sleep by leveraging encephalography (EEG) data from selective spectral frequencies. The techniques, as disclosed herein, may use one or more EEG electrodes, more specifically, a single-channel EEG signal offering a simple and a cost effective solution. The disclosed technique may preprocess this EEG data, extract features and / or derived features for one or more time intervals from selective spectral bands e.g., Delta and Gamma. These extracted features may be normalized and clustered to further determine REM, non-REM, and awake time intervals. By leveraging one or more non-EEG sensors to detect presence of muscle tones for the identified REM sleep intervals and by performing sleep pattern analysis, potential REM intervals may be validated for detection of REM behavior disorder.

The invention relates to the technical field of nano-selenium materials, in particular to a nano-selenium material based on glutathione driving and a preparation method and application thereof.The nano-selenium material is prepared from glutathione and sodium selenite through a one-pot hydrothermal method, the preparation method is simple and easy to implement, and the nano-selenium material is suitable for industrial production. The prepared GSH-Se nanoparticles comprise a nano-selenium core and a glutathione modified shell, and a solution of the GSH-Se nanoparticles has excellent colloidal stability and broad-spectrum free radical scavenging characteristics. Meanwhile, the GSH-Se nanoparticles provided by the invention have the effects of improving Parkinson's disease, promoting mitochondrial homeostasis, relieving neuroinflammation, improving dopaminergic neuron function and motor behavior disorder and the like, and have great clinical application value.

The present application provides a kind of Kunitz polypeptide of coral origin and its encoding gene and application in neuroprotection, belong to polypeptide technical field.The Kunitz polypeptide of coral origin, amino acid sequence is as shown in SEQ ID NO:1.The Kunitz polypeptide has the property of producing specific binding with voltage-gated potassium ion channel Kv1.3, and can effectively repair 6-OHDA induced zebra fish larva movement behavior disorder and neuron damage and improve the increase of neutrophil aggregation and inflammatory factor in zebra fish brain caused by lipopolysaccharide.Therefore, the Kunitz polypeptide can be used as active ingredient in the preparation of drug for preventing and / or treating Parkinson's disease or anti-neuroinflammation.

1,5-dihydro-2,4-benzodiazepine-3-one derivatives, such as a compound represented by formula I, acts on 5-HT2A and 5-HT2C receptors. The selectivity for 5-HT2A is superior or similar to pimavanserin. The derivative is used for treating schizophrenia or Parkinson's disease, dementia-related behavioral disorders, and psychosis. The antipsychotic activity of the compound is equivalent to that of pimavanserin, the side effects of sedation and worsening of exercise are less than those of pimavanserin, and cardiotoxicity is less than that of pimavanserin.

A method for determining whether a subject is at risk of developing a mental and / or behavioral disorder is disclosed. The method may include determining a quantitative value of at least one of 24 blood biomarkers, such as albumin, glycoprotein acetyl, docosahexaenoic acid to total fatty acid ratio, fatty acid unsaturation, docosahexaenoic acid, linoleic acid, monounsaturated fatty acid and / or oleic acid, omega-3 fatty acid, omega-6 fatty acid, in a biological sample obtained from the subject, and comparing the quantitative value of the at least one biomarker with a control sample or control value, where an increase or decrease in the quantitative value of the at least one biomarker compared to the control sample or control value indicates that the subject is at high risk of developing the mental and / or behavioral disorder. The at least one biomarker includes or is glycoprotein acetyl.

The present invention relates to new uses of a 5-HT4 receptor agonist, specifically Isopropyl-3 - { 5- [ 1 -(3 - methoxypropyl) piperidin-4-yl] - [ 1,3,4] oxadiazol-2-yl } - 1 H- indazole (Compound- 1) or a pharmaceutically acceptable salts thereof, for the treatment of dementia due to menopause, senile dementia, cognitive deficits associated with schizophrenia, depression, chemotherapy-induced cognitive impairment and behavioural and psychological symptoms of dementia such as apathy / indifference, agitation, aggression, depression, anxiety, irritability / lability, dysphoria, aberrant motor behaviour, delusions, hallucinations, elation / euphoria, psychosis, disinhibition, sleep and night time behaviour disorders or appetite and eating disorders. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.

The invention relates to the technical field of nerve regulation and control, in particular to a Parkinson's disease REM sleep intervention system based on medial subthalamic nuclear power stimulation, which comprises an image data acquisition module for acquiring preoperative structural magnetic resonance, diffusion tensor imaging and resting state functional magnetic resonance data of a patient; the individualized target region positioning module is used for constructing an individualized brain structure-function connection group of a patient, identifying by using a probabilistic fiber tracking algorithm, and positioning a target region of a subthalamic nucleus abdominal inner side joint region; the electrode planning and parameter generation module is combined with a deep brain electrical stimulation volume activation prediction model to generate a deep brain directional electrode implantation planning path and a stimulation parameter initial scheme; the stimulation parameter regulation and early warning module is used for collecting patient monitoring data, analyzing the relevance between the rapid eye movement sleep behavior disorder symptom improvement degree and stimulation parameters, dynamically adjusting, and periodically monitoring the change of the Monte-eye cognitive assessment scale score of the patient at the same time. Therefore, the problems of extremely high curative effect heterogeneity, fixed postoperative stimulation parameters and the like in the prior art are solved.

Disclosed herein are methods of using coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations for treatment of subjects having behavioral disorders, neurological disorders or mental health disorders. Disclosed herein are methods of treating core and non-core symptoms of behavioral disorders, neurological disorders or mental health disorders. Also disclosed herein are products for use in methods of treatment and methods of making the same.

The present invention provides compositions, systems, and methods for treating or preventing brain disorder with compositions comprising a prebiotic (e.g., green banana flour) and one or both of Lactobacillus reuteri, and Lactobacillus plantarum. In certain embodiments, the brain disorder is selected from neuroinflammation, a neurological disorder, a neuropsychiatric disorder, and a behavioral disorder. In some embodiments, the prebiotic, Lactobacillus reuteri, and Lactobacillus plantarum are provided as a powder inside an ingestible capsule.

Embodiments of the invention relate generally to the treatment of sleep-related disorders. One aspect of the invention includes a method of treating a patient suffering from rapid eye movement (REM) behavior disorder (RBD) comprising: administering to the patient an effective dose of tasimelteon before bedtime.

The invention belongs to the field of medicinal chemistry, and particularly relates to a rumepirone long-acting ester derivative or salt thereof, a preparation method thereof, a pharmaceutical composition thereof and an application of the rumepirone long-acting ester derivative or salt thereof. The derivative of the lumepirone long-acting ester is shown as a formula I, wherein n is an integer from 4 to 14. The invention further relates to a preparation method of the compound shown in the formula I and application of a pharmaceutical preparation of the compound in preparation of drugs for treating mood disorders, sleep disorders, psychotic disorders, excitement and agonism, mental movement states including excitement disorders, behavioral disorders and / or cognitive disorders. The compound provided by the invention has a remarkable long-acting characteristic and ideal pharmaceutical technical properties.

Idiopathic Parkinson's disease (iPD) is a multi-system disorder, and the debilitating motor stage of iPD can be preceded for years by a prodromal stage characterized by non-motor symptoms like REM sleep behavior disorder (RBD) and gastrointestinal symptoms. Widespread immune dysregulation has been reported in clinically diagnosed iPD, but the existence of immune deficits during the prodromal stage has yet to be thoroughly investigated. Here, it was shown that multiple stages of iPD, including the pre-motor prodromal stage, can be stratified according to the immuno-metabolic response to stimulation of peripheral blood immune cells ex vivo. Peripheral blood monocytes from RBD patients displayed increased stimulation-dependent secretion of inflammatory cytokines, including TNF, IL-1β, and IL-8, which peaks in the prodromal stage and successively diminishes as PD progresses. Furthermore, T lymphocyte mitochondrial health was correlated with stimulation-evoked cytokine secretion across patients with RBD, early-stage iPD, and moderate-stage iPD. The results disclosed here have broad implications for mechanistic understanding of how peripheral inflammation may drive disease progression, and it reveals novel biomarkers to enable patient stratification and progression monitoring for clinical trials based on immune endophenotypes.

The application discloses a Caenorhabditis elegans disease model and a construction method and application thereof, and particularly relates to a Caenorhabditis elegans disease model for neurodegenerative diseases, which comprises Caenorhabditis elegans, wherein a fragment of NOTCH2NLC GGC is overexpressed in the Caenorhabditis elegans, the sequence of the fragment is shown as SEQ ID NO. 1, and the neurodegenerative diseases include NIID. The application overcomes the difficulty of cloning GGC repeat sequences, successfully overexpresses 100 GGC repeat sequences of a human NOTCH2NLC gene in Caenorhabditis elegans, and shows similar behavior disorders and premature aging symptoms to human NIID diseases. The model is a good animal model for studying the pathogenic mechanism of GGC repeat sequences of the NOTCH2NLC gene and drug screening.

The present application relates to treatment of Alzheimer's disease. More specifically, the present application relates to a method for treating, palliating or preventing progression of Alzheimer's disease in a subject in need thereof, or improving cognition, suicidality, behavioral disturbance, clinical global impression, and / or functional ability in a subject with Alzheimer's disease, or improving global cognition, the method comprising administering to the subject at least about 50 mg of Montelukast daily, wherein the Montelukast is formulated as an oral dosage film for oral administration.